IRX-2, a natural cytokine biological with multiple components, has been used in preclinical and clinical studies to promote antitumor activity of T lymphocytes. To define cellular mechanisms responsible for antitumor effects of IRX-2, its ability to induce effector T cells (Teff) was examined in a model simulating the tumor microenvironment. An in vitro model containing conventional CD4 +CD25 - cells co-cultured with autologous immature dendritic cells, irradiated tumor cells, and cytokines was used to study differentiation and expansion of regulatory T cells (Treg) and Teff in the presence and absence of IRX-2. Phenotype, suppressor function, signaling, and cytokine production were serially measured using flow cytometry, Western blots, CFSE-based suppressor assays, and Luminex-based analyses. The presence of IRX-2 in the co-cultures promoted the induction and expansion of IFN- γ +Tbet + Teff and significantly (p∈
CITATION STYLE
Schilling, B., Harasymczuk, M., Schuler, P., Egan, J. E., & Whiteside, T. L. (2012). IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model. Journal of Molecular Medicine, 90(2), 139–147. https://doi.org/10.1007/s00109-011-0813-8
Mendeley helps you to discover research relevant for your work.